Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission

Impact on Survival of Early Detection of Recurrence in the Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04298619

Acronym

HOLYFU

Enrollment

123

Registered

2020-03-06

Start date

2001-06-30

Completion date

2019-04-30

Last updated

2020-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Risk, Hodgkin Lymphoma, Relapse

Brief summary

Cohort study enrolled high-risk Hodgkin Lymphoma patients in first relapse after induction therapy followed after remission either with a systemic imaging-based surveillance (Imaging cohort) or with standard clinical-based surveillance (standard cohort).

Interventions

DIAGNOSTIC_TESTStandard cohort: Clinical lab follow-up

DIAGNOSTIC_TESTImaging cohort: integrated imaging follow-up

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* High risk Hodgkin Lymphoma * achievement of complete response to first line therapy

Exclusion criteria

* comorbidities that could impair participation in follow-up procedures

Design outcomes

Primary

Measure	Time frame	Description
Event Free Survival (EFS)	Time period from the first relapse after induction therapy to the date of an event (refractoriness, relapse, or death) or the last follow-up visit after autologous stem cell transplantation (ASCT), up to 2 years	Events: * refractoriness * relapse * death

Secondary

Measure	Time frame	Description
EFS for clinically silent relapses	Time period from the first relapse after induction therapy to the date of an event (refractoriness, relapse, or death) or the last follow-up visit after autologous stem cell transplantation (ASCT), up to 2 years	Events: * refractoriness * relapse * death
Response rate	After salvage therapy and autologous stem cell transplantation (ASCT), up to 2 years	Rate of response

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026